Coenzyme Q10 nanoparticles, preparation method thereof and composition containing said nanoparticles
European Patent Application EP2417970
Pulication Date: Feb. 15, 2012
Assignee: Korea Research Institute of Bioscience and Biotechnology
Provided are a coenzyme Q10 nanoparticle, a method of preparing the same and a composition having the nanoparticle. According to the present invention, coenzyme Q10 may be dissolved in only a water-miscible organic solvent, and easily made into a nano-sized particle and solubilized under a low energy condition, for example, by simple stirring. The coenzyme Q10 may be dispersion-stabilized by an amino acid or protein. The coenzyme Q10 is formed in a nano-sized particle and solubilized, an absorption rate may be increased and simultaneously deliver the amino acid and protein with the nanoparticle. Thus, the coenzyme Q10 nanoparticle can be effectively used in food, cosmetics and medicine.
Coenzyme Q10 is referred to as ubidecarenone, and is a ubiquinone present in higher animals, having 10 isoprene units on a 2,3-dimethoxy-5-methyl-6-polyprenyl-1,4-benzoquinone side chain. It is known that coenzyme Q10 acts not only as a coenzyme, but also as a vitamin-like material improving oxygen efficiency. In addition, it is reported that coenzyme Q10 is essential to produce adenosine triphosphate in mitochondria, and is reported to improve immunity and to have an effect on a heart disease, hyperpiesia, rheumatic valve disease, alveolitis, etc. Coenzyme Q10 contributes to prevention of congestive heart failure, cerebrovascular occlusion and side effects of anticancer drugs (prevention of cardiogenic dysfunction caused by adriamycin), as well as fatigue recovery, regeneration of energy, and antioxidation of active oxygen in a living organism. Further, it is expected to function as an external skin application, thereby showing an anti-aging effect.
Elastin protective polyphenolics and methods of using the same
US Patent 8114829
Publication Date: Feb. 14, 2012
Assignee: Human Matrix Sciences LLC and The Hospital for Sick Children
Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra-tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers.
Compositions of marine botanicals to provide nutrition to aging and environmentally damaged skin
US Patent 8114413
Publication Date: Feb. 14, 2012
Assignee: Mary Kay Inc.
The present invention relates to methods and compositions comprising marine botanicals for treating aged, mature, nutritionally-compromised or environmentally-damaged skin. These methods and compositions provide improvements in the skin's visual appearance, physiological functions, clinical properties and biophysical properties. The present invention relates generally to treatment methods and compositions for improving the skin's visual appearance. In particular, the present invention is directed towards compositions and methods for their use comprising a combination of marine botanicals that can improve the skin's visual appearance by providing improvements in, for example, skin moisture, dryness, surface fine lines, wrinkles, firmness, and/or softness.
In one aspect of this invention, the composition comprises at least one of the following: algae extract, sea fennel or Codium tomentosum extract. The composition can be formulated as a cosmetic compound. The composition can also be comprised in a cosmetic vehicle. The cosmetic vehicle can include an emulsion, a cream, a lotion, a solution, an anhydrous base, a gel or an ointment. The emulsion can be an o/w emulsion or a w/o emulsion. The solution can be an aqueous solution or hydro-alcoholic solution. The anhydrous base can be a lipstick or a powder. The composition can be comprised in an anti-aging product or a moisturizing product. The composition can also be adapted for application one to five times a day during use. In another aspect, the composition can be chemically compatible.
Topical skin care compositions and methods
WIPO Patent Application WO/2012/018865
Publication Date: Feb. 9, 2012
Assignee: Lifeline Skin Care Inc., A Semechkin, NA Turovets, LS Agapova, RA Semechkin and JD Janus
Disclosed are topical compositions containing lysate of human parthenogenetic stem cells (hpSCs), preferably within a liposomal dispersion, that reduce the visible signs of skin aging and/or cellulite. The present invention relates to compositions and methods for reducing the signs of aging of the skin, including facial fine lines, wrinkles, furrows, skin laxity and decreased skin hydration. The present invention also relates to compositions and methods for reducing the appearance of cellulite. The methods of the present invention relate to topical compositions that include lysate of human parthenogenetic stem cells (hpSCs) that are cultivated with or without feeder cells in a culture medium that, in preferred embodiments, is free of xenoreagents.
Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair
WIPO Patent Application WO/2012/017288
Publication Date: Feb. 09, 2012
Assignee: C Ghisalberti
The invention refers to supramolecular complexes formed by polyanionic polymers and spermidine characterized by a ratio of anionic equivalents raging from 101:1 to 107: 1 eq/eq, more preferably from 102: 1 to 104:1 eq/eq, whose components are linked by non-covalent, ionic interactions. Mentioned supramolecular complexes are characterized by high potency in eliciting the fibroblast proliferation. The invention also refers to medicinal/cosmetic compositions comprising the inventive supramolecular complexes for the trophism, maintenance, regeneration, and repair of connective tissues and mucosae in damaged or senescent conditions.
Phenethyl, phenethylene, phenethyne and indanone derivates in cosmetic formulations, especially for use in skin aging processes
WIPO Patent Application WO/2012/016619
Publication Date: Feb. 09, 2012
Assignee: Merck Patent GmbH, T Rudolph, P Buehle and RP Scheurich
The invention relates to the use of one or more compounds, specifically phenethyl, phenethylene and phenethyne derivatives, as an active ingredient precursor in a topical formulation, characterized in that the substance after application is converted to an active ingredient which is more sparingly soluble in the formulation than the active ingredient precursor, and to compositions comprising phenethyl, phenethylene, phenethyne and indanone derivatives.
Personal care compositions comprising a multi-active system for down regulating cytokines irritation
US Patent Application 20120035557
Publication Date: Feb. 9, 2012
Assignee: TW Coffindaffer, BP Heath, HR Kemp and RJ Willicut
Disclosed is a personal care composition comprising a multi-active system for down regulating cytokines comprising at least Camellia sinesis extract, panthenol and a glycyrrhizinate salt. One aspect of the present invention provides for a personal care composition which is suitable for various uses including but not limited to facial or body cleansers or scrubs, pre-shave preparations, shaving gels or foams, moisturizers and lotions, etc.. This composition contains 0.001–8% of a multi-active system for down regulating cytokines comprised of a Camellia sinensis extract (such as white tea extract), panthenol and a glycyrrhizinate salt. In addition, the system contains 50–99.99% of a carrier.
Another aspect of the present invention provides for a method of reducing or controlling skin irritation by applying a personal care composition of the present invention onto skin to form a treated surface. Where the invention is used in a hair removal context, the treated surface can then be subjected to hair removal (i.e., shaving or other) or the treatment can follow the hair removal process.
Chirally correct retinal cyclodextrin acetals for clarifying skin complexion
US Patent Application 20120035130
Publication Date: Feb. 9, 2012
Assignee: Island Kinetics Inc.
The present invention discloses certain chirally correct polyene cyclodextrin acetals and hemiacetals that are effective in providing skin clarification, which is useful for the treatment of acne; skin disfigurements and darkening resulting from acne; skin darkening from cancer, diabetes, radiation treatments, chemotherapy and sunburn; mitochondrial and DNA dysfunction; age spots; loss of cellular antioxidants; skin changes associated with aging including collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles and fine lines; oxidation damage from radiation; damage from free radicals; damage from UV; dry skin; xerosis; ichthyosis; dandruff; brownish spots; keratoses; melasma; lentigines; liver spots; skin pigmentation including pigmented spots, dark circles under the eyes, darkened skin and blemishes; oily skin; warts; eczema; pruritic skin; psoriasis; inflammatory dermatoses; topical inflammation; disturbed keratinization; scalp dryness and combinations thereof.
Apparatus and method for testing relationships between gene expression and physical appearance of skin
US Patent Application 2012003461
Publication Date: Feb. 9, 2012
Assignee: NSE Products, Inc.
The disclosure is directed to apparatus and methods for testing relationships between gene expression and physical appearance of skin and methods of assessing the efficacy of skin anti-aging agents.
In a first aspect, the present disclosure is directed to a method of testing to identify genes associated with one or more physical attributes of skin aging. The methods comprise exposing a first sample of human skin cells or tissue to an agent, determining a first set of expression levels of a plurality of genes in the first sample of human skin, comparing the first set of expression levels to a second set of expression levels, the second set of expression levels corresponding to expression levels of human skin tissue not exposed to the agent, to identify a first subset of genes having a fold change difference in expression level between the exposed and unexposed samples that meets a first, selected biological relevance level, selecting from the first subset of genes a second subset of genes, each gene being associated with a biochemical pathway associated with physical appearance of skin aging, selecting from the second subset of genes, at least one skin attribute subset of genes, each gene in the skin attribute subset being associated with a biochemical pathway relating to the skin attribute that is shown in the comparing step to have been regulated in a more youthful direction for that biochemical pathway and skin attribute, exposing a second sample of human skin tissue to the agent, determining the levels of expression for the at least one skin attribute subset of genes in the second sample of human skin tissue using a method for determining expression levels that is different than that used for the first sample of human skin tissue, and selecting a third subset of genes from the at least one skin attribute subset of genes whose expression levels in the second sample of human skin tissue meet a second, selected biological relevance level and whose direction of regulation conforms to the more youthful direction used in selecting the at least one skin attribute subset of genes.
Elastase inhibitor
United States Patent Application 20120034260
Publication Date: Feb. 9, 2012
Assignee: Shiseido Company, Ltd.
This patent discusses an elastase inhibitor that contains the active ingredients raspberry extract, hydroxyproline and optionally yeast extract. An object of the present invention is to provide an elastase inhibitor that is able to impart resiliency and tightness to skin by inhibiting elastase by using in an external preparation, and is useful as a disease therapeutic agent.
As a result of investigating the elastase inhibitory activity of various plant extracts, the inventor of the present invention found that a solvent extract of raspberry (Rubus idacus L.) has elastase inhibitory activity, and further that this inhibitory activity is synergistically enhanced by the addition of hydroxyproline, thereby leading to completion of the present invention. In addition to the raspberry extract, the elastase inhibitor also contains hydroxyproline, specifically L-hydroxyproline. The optional yeast extract is prepared from yeast which has been cultured in a nutrient medium containing glycosaminoglycan that has been subjected to ultraviolet radiation, hydrogen peroxide treatment or both.
Use of green coffee beans for regulating skin pigmentation disorders
WIPO Patent Application WO/2012/013776
Publication Date: Feb. 2, 2012
Assignee: Nestec S.A., L'Oréal, O Mauroux, A Moodycliffe, F Dionisi and M Guitard
The present invention relates generally to the field of food supplements and/or food products for cosmetic purpose. More specifically, the present invention aims to provide an ingredient containing green coffee beans or an extract thereof for preventing and/or treating hyperpigmentation of skin, skin color imperfections such as age spots and other skin disorders characterized by abnormal pigments. The present invention also aims at improving skin tone as well as providing a skin-lightening or -whitening agent.
Cosmetic compositions comprising oridonin and new cosmetic uses
US Patent Application 20120028916
Publication Date: Feb. 2, 2012
Assignee: Sederma
The present invention related to cosmetic compositions comprising oridonin and new cosmetic uses. Oridonin is used for fighting the signs of cutaneous aging and for slimming. A composition comprising a combination of oridonin and darutigenol or a derivative thereof, in particular darutoside, is disclosed together with the cosmetic use of such composition.
